-
Moleculin Biotech Stock Is Trading Higher After WP1066 Scores Rare Pediatric Disease Tag For Type Of Brain Tumor
Wednesday, April 14, 2021 - 9:38am | 226Read More...The FDA has granted Rare Pediatric Disease Designation to Moleculin Biotech Inc's (NASDAQ: MBRX) WP1066 to treat ependymoma. Ependymoma is a rare type of tumor in the brain or spinal cord and most often occurs in young children. The drug candidate currently received...
-
Why Surface Oncology Shares Spiked 19% Today
Tuesday, March 30, 2021 - 11:49pm | 364Read More...Shares of Surface Oncology Inc. (NASDAQ: SURF), a clinical-stage biopharma company, gained more than 19% in the extended session on Tuesday. What Happened: The spike in shares came after the Cambridge, Massachusetts-based company said Tuesday that one of its lead therapeutic candidates, SRF617, has...
-
BridgeBio Pharma Gets First FDA-Approval For Rare Genetic Metabolic Disorder
Monday, March 1, 2021 - 6:17am | 198Read More...BridgeBio Pharma Inc (NASDAQ: BBIO) and affiliate Origin Biosciences Inc have received the FDA approval for Nulibry (fosdenopterin) Injection to reduce the risk of mortality in patients with molybdenum cofactor deficiency (MoCD) Type-A. MoCD is a rare metabolic...
-
AIM ImmunoTech Gets Orphan Drug Tag For Ampligen In Pancreatic Cancer
Wednesday, February 24, 2021 - 2:57pm | 308Read More...AIM ImmunoTech Inc's (NYSE: AIM) subsidiary, NV Hemispherx Biopharma Europe, has received formal notification from the European Commission for Orphan Medicinal Product Application for Ampligen as a treatment for pancreatic cancer. Among other benefits, products with Orphan...
-
Cerecor's CERC-803 Nabs US Orphan Drug Tag In Rare Immunodeficiency Disorder
Tuesday, February 2, 2021 - 10:12am | 187Read More...The FDA has designated Fast Track status to Cerecor Inc's (NASDAQ: CERC) CERC-803 for the treatment of Leukocyte Adhesion Deficiency Type 2 (LAD-II), a rare congenital disorder due to mutations in the SLC35C1 gene, and characterized by frequent infections, persistent...
-
Shares Of Pluristem Therapeutics Surging Following Receipt Of Orphan Drug Designation
Thursday, December 31, 2015 - 11:20am | 191Read More...Shares Pluristem Therapeutics Inc. (NASDAQ: PSTI), a biotherapeutics company that develops off-the-shelf allogeneic cell therapy products, surged higher by more than 16 percent on Thursday. Pluristem Therapeutics announced on Thursday that the U.S. Food and Drug Administration (FDA) granted the...
-
Why Shares of Ignyta Are Trading Higher
Monday, December 29, 2014 - 10:07am | 234Read More...Shares of Ignyta Inc (NASDAQ: RXDX) were trading higher by more than 6 percent during Monday's pre-market session after the company announced that the FDA designated its entrectinib, a lead product candidate an Orphan Drug for the treatment of neuroblastoma. The FDA grants Orphan Drug...
